UnitedHealth Stock Drops Despite Strong Earnings Rebound Amid Medical Cost Concerns

UnitedHealth Group's latest earnings report showed a strong rebound in quarterly adjusted earnings per share and operating earnings, but the company's stock price slipped by about 1.6% on the day of the release. The market seems to be discounting the earnings strength and raised full-year guidance, instead focusing on lingering concerns about medical cost trends.

The Q2 2026 earnings report showed a significant increase in revenue and net income, with adjusted EPS reaching $6.38, up about 61% from last year's quarter. However, the medical care ratio remained high at 86.7%, including $860 million of favorable prior period development.

Bulls argue that UnitedHealth Group is in an operational recovery, with Medicare Advantage and Optum showing signs of improvement. The company's management now expects 2026 Medicare margins above 3% and a smaller enrollment decline than feared. On the other hand, bears focus on stubborn medical cost pressure, fragile commercial margins, and heavier regulatory risk around vertical integration.

The stock's drop suggests that investors are still treating these concerns as active overhangs. The UnitedHealth bear case highlights the challenges facing the company, including commercial medical cost trends above 11% and Medicaid margins remaining in a small loss range for 2026.